The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.
bone marrow transplant
haploidentical
immunotherapy
pediatric
severe aplastic anemia
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
08
03
2024
received:
04
12
2023
accepted:
29
04
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
ppublish
Résumé
The goal of this study was to assess the effect of donor type and pre-transplant immunotherapy (IST) on outcomes of hematopoietic stem cell transplantation (HSCT) for children and young adults with severe aplastic anemia (SAA). This retrospective, multi-center study included 52 SAA patients, treated in 5 pediatric transplant programs in Florida, who received HSCT between 2010 and 2020 as the first- or second-line treatment. The median age at HSCT for all 52 patients was 15 years (range 1-25). The 3-year overall survival (OS) by donor type were as follows: 95% [95% CI 85.4-99] for matched related donors (MRD) (N = 24), 84% [95% CI 63.5-99] for haploidentical (N = 13), and 71% [95% CI 36-99] for matched unrelated donors (MUD) (N = 7). The 3-year OS was 81% [95% CI 69.7-99] for all patients, 90.5% [95% CI 79.5-99] for non-IST patients (N = 27), and 70% [95% CI 51-99] for IST patients (N = 24) (log-rank p = .04). Survival of haploidentical HSCT (haplo-HSCT) recipients with post-transplant cyclophosphamide (PTCy) (N = 13) was excellent for both groups: 100% for non-IST patients (N = 3) and 80% for IST patients (N = 10). The 3-year OS for patients with previous IST by donor type in groups where >5 patients were available was 78.8% [95% CI 52.3-99] for haplo-HSCT (N = 10) and 66.7% [95% CI 28.7-99] for MUD (N = 6). Although it appears that patients receiving HSCT ≥6 months after the start of IST had worse survival, the number of patients in each category was small and log-rank was not significant(p = .65). Patients receiving MUD and haplo-HSCT with PTCy had similar outcomes, suggesting that haplo-HSCT with PTCy could be included in randomized trials of upfront IST versus alternative donor HSCT.
Sections du résumé
BACKGROUND
BACKGROUND
The goal of this study was to assess the effect of donor type and pre-transplant immunotherapy (IST) on outcomes of hematopoietic stem cell transplantation (HSCT) for children and young adults with severe aplastic anemia (SAA).
METHODS
METHODS
This retrospective, multi-center study included 52 SAA patients, treated in 5 pediatric transplant programs in Florida, who received HSCT between 2010 and 2020 as the first- or second-line treatment.
RESULTS
RESULTS
The median age at HSCT for all 52 patients was 15 years (range 1-25). The 3-year overall survival (OS) by donor type were as follows: 95% [95% CI 85.4-99] for matched related donors (MRD) (N = 24), 84% [95% CI 63.5-99] for haploidentical (N = 13), and 71% [95% CI 36-99] for matched unrelated donors (MUD) (N = 7). The 3-year OS was 81% [95% CI 69.7-99] for all patients, 90.5% [95% CI 79.5-99] for non-IST patients (N = 27), and 70% [95% CI 51-99] for IST patients (N = 24) (log-rank p = .04). Survival of haploidentical HSCT (haplo-HSCT) recipients with post-transplant cyclophosphamide (PTCy) (N = 13) was excellent for both groups: 100% for non-IST patients (N = 3) and 80% for IST patients (N = 10). The 3-year OS for patients with previous IST by donor type in groups where >5 patients were available was 78.8% [95% CI 52.3-99] for haplo-HSCT (N = 10) and 66.7% [95% CI 28.7-99] for MUD (N = 6). Although it appears that patients receiving HSCT ≥6 months after the start of IST had worse survival, the number of patients in each category was small and log-rank was not significant(p = .65).
CONCLUSIONS
CONCLUSIONS
Patients receiving MUD and haplo-HSCT with PTCy had similar outcomes, suggesting that haplo-HSCT with PTCy could be included in randomized trials of upfront IST versus alternative donor HSCT.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14784Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American pediatric aplastic anemia consortium study. Haematologica. 2019;104(10):1974‐1983.
Camitta BM, Thomas ED, Nathan DG. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63‐70.
Niemeyer CM, Bauman I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2011;2011:84‐89.
Klein OR, Chen AR, Gamper C, et al. Alternative‐donor hematopoietic stem cell transplantation with post‐transplantation cyclophosphamide for nonmalignant disorders. Biol BMT. 2016;22(5):895‐901.
Majhail NS, Nayyar S, Santibanez ME, Murphy EA, Denzen EM. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2011;47(11):1385‐1390.
Kim SY, Le Rademacher J, Antin JH, et al. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014;99(12):1868‐1875.
Townsley D, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540‐1550.
Tichelli A, Schrenzenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin, cyclosporine, with or without G‐CSF: a study of the SAA working party of the European group of blood and marrow transplantation. Blood. 2011;117(17):4434‐4441.
Williams D, Pulsipher M, Shaw B. A phase III randomized trial comparing unrelated donor bone marrow transplantation with immune suppressive therapy for newly diagnosed pediatric and young adult patients with severe aplastic anemia (TransIT, BMT CTN 2202). NCT05600426. 2023 https://clinicaltrials.gov/study/NCT05600426
Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825‐828.
Shulman HM, Sullivan KM, Weiden PL, et al. Chronic GVHD syndrome in man: a long term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204‐217.
Gu Z, Wang L, Yuan L, et al. Similar outcomes after haploidentical transplantation with post‐transplant cyclophosphamide versus HLA‐matched transplantation: a meta‐analysis of case‐control studies. Oncotarget. 2017;8(38):63574‐63586.
McCurdy SR, Kasamon YL, Kanakry CG, et al. Comparable composite endpoints after HLA‐matched and HLA‐haploidentical transplantation with posttransplantation cyclophosphamide. Haematologica. 2017;102:391‐400.
Xu ZL, Xu LP, Wu DP, et al. Comparable long‐term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry‐based study. Haematologica. 2022;107(12):2918‐2927.
DeZern AE, Zahurak M, Symons HJ, et al. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023;141(25):3031‐3038.
Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. Br J Haematol. 2015;171(4):585‐594.
Yang S, Yuan X, Ma R, et al. Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA‐matched sibling donor. Biol Blood Marrow Transplant. 2019;25(5):975‐980.
Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem‐cell transplantation from an alternative donor as second‐line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054‐1059.
Dezern AE, Eapen M, Wu J, et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicenter, single‐arm, phase 2 trial. Lancet Haematol. 2022;9(9):660‐669.